Related Experiment Videos
Benzimidazolone p38 inhibitors
Mark A Dombroski1, Michael A Letavic, Kim F McClure
1Pfizer Global Research and Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, USA.
Bioorganic & Medicinal Chemistry Letters
|March 12, 2004
Summary
Researchers synthesized novel benzimidazolone inhibitors targeting p38 alpha kinase. These compounds show potent activity, binding to Met109 similarly to existing inhibitors, indicating a promising new class of drugs.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Pharmacology
Background:
- p38 alpha kinase is a key regulator of inflammatory responses.
- Developing selective inhibitors for p38 alpha is crucial for treating inflammatory diseases.
- Existing inhibitors often utilize heterocyclic scaffolds for binding.
Purpose of the Study:
- To describe the synthesis of a novel series of benzimidazolone-based inhibitors.
- To evaluate the in vitro activity of these compounds against p38 alpha kinase.
- To elucidate the structure-activity relationship (SAR) and binding mode of the novel inhibitors.
Main Methods:
- Chemical synthesis of benzimidazolone derivatives.
- In vitro enzyme inhibition assays to determine p38 alpha activity.
- Structure-activity relationship analysis based on binding data.
Main Results:
- A novel series of benzimidazolone inhibitors targeting p38 alpha was successfully synthesized.
- These compounds exhibit potent in vitro p38 alpha inhibitory activity.
- The binding mode involves the benzimidazolone carbonyl acting as a hydrogen bond acceptor to Met109, similar to known inhibitors.
Conclusions:
- Benzimidazolones represent a novel and effective chemotype for p38 alpha inhibition.
- The observed binding mode supports the potential of these compounds as therapeutic agents.
- Further development of these benzimidazolone inhibitors may lead to new anti-inflammatory drugs.